These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6146075)

  • 1. Nalidixic acid analogues and Shigella.
    Bannatyne RM; Toma S; Cheung R
    Lancet; 1984 Jul; 2(8395):172-3. PubMed ID: 6146075
    [No Abstract]   [Full Text] [Related]  

  • 2. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
    Barry AL; Jones RN
    Antimicrob Agents Chemother; 1984 Jun; 25(6):775-7. PubMed ID: 6234858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Shrire L; Saunders J; Traynor R; Koornhof HJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):328-32. PubMed ID: 6237900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Delmee M; Avesani V
    Antimicrob Agents Chemother; 1986 Feb; 29(2):374-5. PubMed ID: 2940968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens.
    Diez-Enciso M; Mas-Jimenez G; Velasco-Cerrudo A; Gutierrez-Altes A
    Eur J Clin Microbiol; 1984 Aug; 3(4):367. PubMed ID: 6237905
    [No Abstract]   [Full Text] [Related]  

  • 11. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C; Richmond S; Bailey J
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance of shigella to nalidixic acid & fluorinated quinolones.
    Thirunarayanan MA; Jesudason MV; John TJ
    Indian J Med Res; 1993 Nov; 97():239-41. PubMed ID: 8144205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.
    Taylor DE; Ng LK; Lior H
    Antimicrob Agents Chemother; 1985 Nov; 28(5):708-10. PubMed ID: 3004325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin.
    Fallon RJ; Brown WM
    J Antimicrob Chemother; 1985 Jun; 15(6):787-9. PubMed ID: 3161857
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid.
    De Mol P; Mets T; Lagasse R; Vandepitte J; Mutwewingabo A; Butzler JP
    J Antimicrob Chemother; 1987 May; 19(5):695-8. PubMed ID: 3301783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.